- Home
- SRFM vs ELTX Comparison
SRFM vs ELTX Comparison
Compare SRFM & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | ELTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 134.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRFM | ELTX |
|---|---|---|
| Price | $2.76 | $8.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.81 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 5.5M | 93.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $108,158,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.77 | $4.60 |
| 52 Week High | $9.91 | $12.62 |
Technical Indicators
Market Signals| Indicator | SRFM | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 49.78 |
| Support Level | $1.88 | $7.48 |
| Resistance Level | $3.50 | $8.59 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 55.56 | 57.70 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.